News/Blogs
RSV Immunization Program Update: What You Need to Know
We’ve updated our Core Immunization Program to include RSV immunizations, expanding beyond our previous coverage of flu, pneumonia, and shingles vaccines. This update reflects recent advances in RSV prevention and aligns with current CDC recommendations.
Understanding RSV
RSV is a common respiratory virus that affects people of all ages, causing cold-like symptoms, although it can lead to serious complications and hospitalization. Infants younger than 6 months and older adults with certain risk factors are most susceptible. Peak RSV season typically occurs in December and January, alongside other respiratory viruses. Distinguishing RSV from the common cold, flu, and COVID-19 can be challenging due to symptom similarities.
The Changing Landscape for Infant Protection
Prevention options for infants have undergone significant improvements. Since 1998, Synagis (palivizumab) has served as the primary protection for high-risk infants. It requires up to 5 monthly injections during RSV season at a cost exceeding $10,000 and typically requiring prior authorization.
Two newer immunizations entered the market—Beyfortus in 2023 and Enflonsia in 2025—offering broader coverage for children with longer protection from a single shot costing approximately $556, and prior authorization is typically not required. Additionally, pregnant individuals can receive Abrysvo during pregnancy to pass RSV protection to their babies.
The American Academy of Pediatrics updated its recommendations in July 2025. The update designates Beyfortus and Enflonsia as first-line treatments while Synagis will be discontinued at the end of 2025.
Adult Protection Finally Available
For the first time, adults have RSV vaccine options. Three vaccines are now available—Abrysvo and Arexvy (both approved May 2023) and mResvia (approved June 2024). The CDC recommends vaccination for adults aged 75 and older, as well as adults aged 50-74 with certain risk factors, to prevent lung infections and potential hospitalization.
These adult vaccines are administered as a single dose, at approximately $300, and are not annual vaccines. Each dose provides protection for approximately 2 years, although additional data is needed for long-term evaluation.
Moving Forward
The CDC continuously reviews safety and efficacy data as RSV immunization protection evolves. We monitor this guidance and update our immunization program accordingly to ensure your clients have access to current prevention options.
To partner with a PBM that stays on top of health trends, reach out today.
About Serve You Rx®
Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing what’s best for its clients. With a fervent focus on those it serves, including insurance brokers, consultants, third-party administrators, and their clients, Serve You Rx delivers exceptional service and tailored, cost-effective benefit solutions. Independent and privately held for nearly 40 years, Serve You Rx can implement new groups in 30 days or less and say “yes” to a wide variety of viable solutions. Known for its adaptability, quality, and client-centricity, Serve You Rx aims to be a benchmark for better client service.
